CoChat

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

Open access
El-Hayek, Youssef H., Wiley, Ryan E., Khoury, Charles P., Daya, Ritesh P., Ballard, Clive, Evans, Alison R., Karran, Michael, Molinuevo, José Luis, Norton, Matthew, Atri, Alireza · 2019 · Journal of Alzheimer's Disease

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

Abstract

While it is generally understood that Alzheimer's disease (AD) and related dementias (ADRD) is one of the costliest diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease, its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions to mitigate this looming public health crisis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-190426

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Tip of the iceberg: Measured societal costs represent only a proportion of the total burden of ADRD. Most studies that have assessed the costs of ADRD have focused on patients with a dementia diagnosis and have generally demonstrated that costs increase with disease severity. However, such studies may not fully capture the total impact of ADRD for three reasons. First, the magnitude of indirect costs (e.g., lost productivity, informal caregiving) can vary widely depending on the methodologies and assumptions used. Second, cost of illness studies may not be measuring the full spectrum ADRD costs; for example, financial impacts on households (e.g., reduced savings, financial exploitation, out of pocket costs, unemployment) may have substantial and intergenerational effects on the economy. Finally, some studies suggest that costs begin to accrue years before a dementia diagnosis, albeit at a comparatively lower rate than those in advanced disease stages. However, given the long preclinical stage (estimated at 10–20 years), it is possible that these ‘hidden costs’ represent a substantial fraction of cumulative ADRD costs. Given the current evidence base, we cannot accurately gauge the size of these ‘hidden costs’, making it challenging to quantify the full burden of ADRD and the potential value of health interventions and policies.
Fig.1 Tip of the iceberg: Measured societal costs represent only a proportion of the total burden of ADRD. Most studies that have assessed the costs of ADRD have focused on patients with a dementia diagnosis and have generally demonstrated that costs increase with disease severity. However, such studies may not fully capture the total impact of ADRD for three reasons. First, the magnitude of indirect costs (e.g., lost productivity, informal caregiving) can vary widely depending on the methodologies and assumptions used. Second, cost of illness studies may not be measuring the full spectrum ADRD costs; for example, financial impacts on households (e.g., reduced savings, financial exploitation, out of pocket costs, unemployment) may have substantial and intergenerational effects on the economy. Finally, some studies suggest that costs begin to accrue years before a dementia diagnosis, albeit at a comparatively lower rate than those in advanced disease stages. However, given the long preclinical stage (estimated at 10–20 years), it is possible that these ‘hidden costs’ represent a substantial fraction of cumulative ADRD costs. Given the current evidence base, we cannot accurately gauge the size of these ‘hidden costs’, making it challenging to quantify the full burden of ADRD and the potential value of health interventions and policies.CC BY-NC · PubMed Central
Fig.2 The cost of ADRD across the spectrum of the disease to key stakeholders groups. The nature (i.e., direct, indirect, intangible) and magnitude (i.e., low, medium, high) of ADRD costs incurred by different stakeholders varies by the stage of disease (i.e., preclinical, prodromal, mild, moderate, severe).
Fig.2 The cost of ADRD across the spectrum of the disease to key stakeholders groups. The nature (i.e., direct, indirect, intangible) and magnitude (i.e., low, medium, high) of ADRD costs incurred by different stakeholders varies by the stage of disease (i.e., preclinical, prodromal, mild, moderate, severe).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. World Health Organization. First WHO Ministerial Conference on Global Action Against Dementia.

Cited by

See all 216

Metadata

Authors
El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A.
Affiliations
  • Shift Health, Toronto, ON, Canada
  • McMaster University (CA)
  • University of Exeter (GB)
  • Alzheimer’s Research UK (GB)
  • Barcelonaβeta Brain Research Center, Barcelona, Spain
  • Brigham and Women's Hospital (US)
Corresponding author
Atri, Alireza
Venue
Journal of Alzheimer's Disease
Published
2019-07-23
Volume
70
Issue
2
Pages
323-341
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2954682095
Cited by
216
References
132
Citations by year
2026: 10 · 2025: 33 · 2024: 28 · 2023: 34 · 2022: 47 · 2021: 40 · 2020: 23 · 2019: 1
FWCI
4.66
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
Funders
  • F. Hoffmann-La Roche
  • National Institute on Aging (P30AG019610)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, related dementias
MeSH terms
Stakeholder Participation, Alzheimer Disease, Dementia, Humans, Socioeconomic Factors, Global Health, Health Care Costs, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.